Symbinas Pharmaceuticals Incis A Privately Held Biopharmaceutical Company Based In Floridafounded In 2018The Company Is Dedicated To Developing Innovative Therapeutics For Significant Unmet Medical Needsparticularly In Nervous System Diseasesinspired By Personal Experiences With Traumatic Brain Injurytbi Symbinas Focuses On Creating Effective Treatments For Conditions Like Concussion And Tbiwhich Have Seen Little Advancement In Decades The Company S Lead Product Candidatesmb 603Is Designed To Treat Concussion And Tbiwith Plans To Utilize Fda Accelerated Approval Pathways For A Market Entry Within 24 Monthsadditionallysymbinas Is Developing Smb 710Targeting Chronic Tbi And Showing Potential For Treating Alzheimerae S And Parkinsonae S Diseasestheir Expansive Pipeline Also Includes Candidates For Depression And Schizophreniareflecting A Broad Commitment To Addressing Various Nervous System Disorderssymbinas Aims To Serve A Global Patient Populationtargeting The Substantial $400 Billion Market For Concussion And Tbi Treatments
